The China Computational Biology Market was valued at USD 427.8 million in 2024 and is estimated to grow at a CAGR of 14.3% to reach USD 1.6 billion by 2034.
The rapid expansion is driven by the rising use of computational designs in clinical trials, increasing costs and time pressures in drug development, supportive government initiatives, and a growing volume of omics data and bioinformatics research. Computational biology merges high-performance computing, data analytics, and algorithm development to model biological systems, analyze complex datasets from genomics and proteomics, and accelerate drug discovery, disease modeling, and personalized medicine. Continuous advancements in bioinformatics and computational tools are transforming life sciences research by enabling the integration of multi-omics datasets, providing comprehensive insights into biological systems, and streamlining the identification of disease mechanisms and therapeutic targets. Researchers increasingly rely on these platforms to shorten R&D cycles and enhance predictive accuracy, making computational biology an essential component of modern pharmaceutical and biotechnology research.
In 2024, the analysis software and services segment held a 45.4% share owing to its essential role in enabling efficient processing, interpretation, and visualization of large biological datasets. These solutions combine advanced algorithms, machine learning, and cloud-based platforms to support multi-omics analysis, drug discovery simulations, and personalized medicine applications. The growing complexity of biological data and the need for timely insights in clinical trials have made software and services a critical component of research infrastructure. Increasing adoption of AI-driven predictive analytics and compatibility with laboratory information systems further boost demand for this segment.
The drug discovery and disease modeling segment is projected to grow at a CAGR of 14.7% from 2025 to 2034. The growth is fueled by the increasing reliance on computational platforms to simulate molecular interactions and predict therapeutic outcomes, which significantly reduces R&D timelines and costs. Integration of AI-based predictive models with multi-omics datasets enables more accurate disease modeling, facilitating the development of targeted and personalized therapies.
Key players in the China Computational Biology Market include Danaher, QIAGEN, BIO-RAD, Thermo Fisher Scientific, CERTARA, DNAnexus, Schrödinger, Cadence, Hansoh Pharma, Instem, and Dassault Systèmes. Companies in the China Computational Biology Market are leveraging several strategies to enhance their market presence. They are investing heavily in research and development to improve AI-driven predictive tools, bioinformatics platforms, and multi-omics integration capabilities. Strategic partnerships with pharmaceutical and biotechnology firms allow them to deploy their solutions in real-world clinical trials and drug discovery pipelines. Firms are also focusing on expanding cloud-based analytics, enhancing software interoperability, and offering scalable platforms to meet diverse research needs. Additionally, mergers, acquisitions, and collaborations with academic institutions strengthen their technological expertise and broaden market reach, while targeted investments in regulatory compliance and localized solutions help capture a larger share of the Chinese computational biology market.
This product will be delivered within 2-4 business days.
The rapid expansion is driven by the rising use of computational designs in clinical trials, increasing costs and time pressures in drug development, supportive government initiatives, and a growing volume of omics data and bioinformatics research. Computational biology merges high-performance computing, data analytics, and algorithm development to model biological systems, analyze complex datasets from genomics and proteomics, and accelerate drug discovery, disease modeling, and personalized medicine. Continuous advancements in bioinformatics and computational tools are transforming life sciences research by enabling the integration of multi-omics datasets, providing comprehensive insights into biological systems, and streamlining the identification of disease mechanisms and therapeutic targets. Researchers increasingly rely on these platforms to shorten R&D cycles and enhance predictive accuracy, making computational biology an essential component of modern pharmaceutical and biotechnology research.
In 2024, the analysis software and services segment held a 45.4% share owing to its essential role in enabling efficient processing, interpretation, and visualization of large biological datasets. These solutions combine advanced algorithms, machine learning, and cloud-based platforms to support multi-omics analysis, drug discovery simulations, and personalized medicine applications. The growing complexity of biological data and the need for timely insights in clinical trials have made software and services a critical component of research infrastructure. Increasing adoption of AI-driven predictive analytics and compatibility with laboratory information systems further boost demand for this segment.
The drug discovery and disease modeling segment is projected to grow at a CAGR of 14.7% from 2025 to 2034. The growth is fueled by the increasing reliance on computational platforms to simulate molecular interactions and predict therapeutic outcomes, which significantly reduces R&D timelines and costs. Integration of AI-based predictive models with multi-omics datasets enables more accurate disease modeling, facilitating the development of targeted and personalized therapies.
Key players in the China Computational Biology Market include Danaher, QIAGEN, BIO-RAD, Thermo Fisher Scientific, CERTARA, DNAnexus, Schrödinger, Cadence, Hansoh Pharma, Instem, and Dassault Systèmes. Companies in the China Computational Biology Market are leveraging several strategies to enhance their market presence. They are investing heavily in research and development to improve AI-driven predictive tools, bioinformatics platforms, and multi-omics integration capabilities. Strategic partnerships with pharmaceutical and biotechnology firms allow them to deploy their solutions in real-world clinical trials and drug discovery pipelines. Firms are also focusing on expanding cloud-based analytics, enhancing software interoperability, and offering scalable platforms to meet diverse research needs. Additionally, mergers, acquisitions, and collaborations with academic institutions strengthen their technological expertise and broaden market reach, while targeted investments in regulatory compliance and localized solutions help capture a larger share of the Chinese computational biology market.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Tool, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Services, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The companies profiled in this China Computational Biology market report include:- BIO-RAD
- Cadence
- CERTARA
- Danaher
- DASSAULT SYSTEMES
- DNAnexus
- HANSOH PHARMA
- Illumina
- Instem
- QIAGEN
- Schrödinger
- Thermo Fisher SCIENTIFIC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 90 |
| Published | October 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 427.8 Million |
| Forecasted Market Value ( USD | $ 1600 Million |
| Compound Annual Growth Rate | 14.3% |
| Regions Covered | China |
| No. of Companies Mentioned | 13 |
